Qorvo News

  1. Qorvo® Biotechnologies Receives FDA Emergency Use Authorization For Rapid COVID-19 Antigen Testing 4/13/2021

    Qorvo® a leading provider of innovative radio frequency (RF) solutions that connect the world, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the Qorvo Omnia™ SARS-CoV-2 Antigen Test. The test is authorized for the qualitative detection of nucleocapsid viral antigens from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of COVID-19.

  2. RFMW and Qorvo Cosponsor 2019 ARMMS Conference 5/9/2019

    RFMW, Ltd. announces participation and sponsorship of the 2019 ARMMS Conference.

  3. U.S. Department Of Defense Expands Qorvo® Microelectronics Trusted Source Status 2/6/2017

    Qorvo® recently earned continued Trusted Source Category 1A accreditation through 2018 from the U.S. Department of Defense (DoD). The company is one of only five accredited suppliers for both gallium nitride (GaN) and gallium arsenide (GaAs).